Tag: AltuVIIIO

Once-weekly Altuviiio, a new kind of factor VIII therapy for haemophilia A that provides considerable bleed prevention, has been approved by the US FDA.

Altuviiio [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl], formerly known as efanesoctocog alfa, is a first-in-class, highly sustained factor VIII replacement therapy that has received FDA approval. For both adults and children with haemophilia A, the use of altuviiio is recommended…

Back to top

Registration Form


This will close in 0 seconds

This will close in 0 seconds

WhatsApp Join Telegram